AstraZeneca announced top─line results from the pooled cardiovascular (CV) safety analyses of the global phase III programme for roxadustat, a first─in─class hypoxia─inducible─factor prolyl hydroxylase inhibitor
AstraZeneca announced top─line results from the pooled cardiovascular (CV) safety analyses of the global phase III programme for roxadustat, a first─in─class hypoxia─inducible─factor prolyl hydroxylase inhibitor
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
